Cummins: Jefferies maintains 'Buy' ratings on Cummins, cuts target price to Rs 4,975.

Godrej Properties: Jefferies maintains 'Buy' ratings on Godrej Properties, cuts target price to Rs 2,700.

Kaynes: Jefferies maintains 'Buy' ratings on Kaynes with a target price of Rs 5,940.

Tata Motors PV: Jefferies maintains 'Underperform' ratings on Tata Motors PV, hikes target price to Rs 310.

Hitachi Energy: Jefferies maintains 'Buy' ratings on Hitachi Energy with a target price of Rs 25000.

Uno Minda: Goldman Sachs stays bullish on Uno Minda, raises target price to ₹1,500

Blackbuck: Morgan Stanley maintains Equal Weight on Blackbuck with target price at ₹653

Astral: Morgan Stanley stays neutral on Astral, maintains Equal Weight with target price at ₹1,461

Aditya Birla Fashion: Morgan Stanley remains positive on Aditya Birla Fashion, maintains Overweight with target price at ₹131

REC: Morgan Stanley remains positive on REC, trims target price to ₹495

PB Fintech: Morgan Stanley maintains 'Underweight' ratings on PB Fintech with target price of Rs 1,370.

Bharti Airtel: Morgan Stanley maintains 'Overweight' ratings on Airtel with a target price of Rs 2,435

Nykaa: Morgan Stanley maintains 'Overweight' ratings on Nykaa, hikes target price to Rs 286.

Alembic Pharma: Plans New Agreements To Increase Production For Injectables And Oncology Products Over The Next Year And A Half, With More Opportunities Expected In Two Years. The Company Aims To Launch 4 To 5 More Products In The U.S. In Q4 And Will Release Its First U.S. Branded Product, Pivya, In February 2026.

Alembic Pharma: Co's U.S. Business Aims For 10% To 12% Growth In The Full Year And Could Reach Mid-Teens Growth (10% To 15%) In The Next Two To Three Years. The Branded Product Pivya Is Set To Launch In The U.S. In Q4 (February 2026), With Anticipated Increase In Script And Market Share Over The Coming 12 To 18 Months, Nonetheless Facing Short-Term Profitability Challenges

Alembic Pharma: Projects Full-Year R&D Expenses Between INR 600 To 650 Crores, With Next Year's R&D Spending Expected To Be Around 8% To 9% Of Total Revenue. The Indian Market Is Expected To Align With Growth Rates By Q1 Of The Next Financial Year, Mainly Due To Enhanced Operations.

Tembo Global: Co's New Vasai Manufacturing Plant Expects 90% to 100% Capacity Utilization in 2 to 3 Years, With a Strong Order Book of ₹1,484 Crore for Revenue Visibility for the Next 1 to 2 Years. No Extra Capital Expenses Planned Beyond Current Solar and Defense Projects, and Working Capital Days Expected to Stay Steady.